Surface Oncology, Inc. Common Stock
SURF
SURF was delisted on the 7th of September, 2023.
84 hedge funds and large institutions have $48.6M invested in Surface Oncology, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 32 closing their positions.
559% more call options, than puts
Call options by funds: $481K | Put options by funds: $73K
17% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less funds holding
Funds holding: 103 → 84 (-19)
48% less capital invested
Capital invested by funds: $92.9M → $48.6M (-$44.4M)
53% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$2.17M |
| 2 |
Millennium Management
New York
|
+$1.46M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$1.38M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$872K |
| 5 |
Barclays
London,
United Kingdom
|
+$676K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$6.76M |
| 2 |
BlackRock
New York
|
-$3.15M |
| 3 |
Morgan Stanley
New York
|
-$1.46M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$1.44M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$877K |
SURF Hedge Fund Activity: Q2 2022 in Review
84 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q2 2022, worth a combined $48.6M — down 48% from $92.9M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of SURF and 15 opened new positions — a net loss of 17 holders — while 23 trimmed existing stakes and 27 added.
The largest buyer was Citigroup, adding an estimated $2.17M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $6.76M sold.
- 84 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q2 2022, down from 103 in Q1 2022.
- Funds reported $48.6M of Surface Oncology, Inc. Common Stock stock for Q2 2022, down 48% quarter-over-quarter.
- 15 funds opened new Surface Oncology, Inc. Common Stock positions in Q2 2022 and 32 closed out, a net change of -17 holders.
- The largest Surface Oncology, Inc. Common Stock buyer in Q2 2022 was Citigroup, an estimated $2.17M added.
- The largest Surface Oncology, Inc. Common Stock seller in Q2 2022 was Octagon Capital Advisors, an estimated $6.76M sold.
Based on aggregated 13F filings for Q2 2022.